Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H17Cl2N3O |
| Molecular Weight | 314.21 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=CC(Cl)=C1N(C2CCCCO2)C3=NCCN3
InChI
InChIKey=NYQGJEQCYOJBPV-UHFFFAOYSA-N
InChI=1S/C14H17Cl2N3O/c15-10-4-3-5-11(16)13(10)19(14-17-7-8-18-14)12-6-1-2-9-20-12/h3-5,12H,1-2,6-9H2,(H,17,18)
| Molecular Formula | C14H17Cl2N3O |
| Molecular Weight | 314.21 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Piclonidine is imidazoline derivative. Piclonidine has a relative specificity for the hypotensive action and thus indicate that the compound differs from the chemical congener clonidine which has other pharmacological effects involving several peripheral or centrally regulated autonomic functions. Unlike clonidine, this chemically related compound did not evoke hypertensive episodes or cause sedation in animals up to the oral dose of 1 mg/kg.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:10:37 GMT 2025
by
admin
on
Mon Mar 31 18:10:37 GMT 2025
|
| Record UNII |
R7P4D56J1Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C270
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
R7P4D56J1Z
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
4869
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
72467-44-8
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
SUB09811MIG
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
100000082474
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
68914
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
276-672-6
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
DTXSID00868142
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
C66381
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106921
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |